Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. The company is headquartered in Stockholm, Stockholm and currently employs 1,937 full-time employees. The company went IPO on 2006-09-15. The firm develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The firm has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
Follow-Up Questions
BIOVF hissesinin fiyat performansı nasıl?
BIOVF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Swedish Orphan Biovitrum AB (publ) için ana iş temaları veya sektörler nelerdir?
Swedish Orphan Biovitrum AB (publ) Biotechnology endüstrisine ait ve sektör Health Care 'dir
Swedish Orphan Biovitrum AB (publ) 'in piyasa değerlemesi nedir?
Swedish Orphan Biovitrum AB (publ) 'in mevcut piyasa değerlemesi $NaN 'dir
Swedish Orphan Biovitrum AB (publ) al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 17 analist Swedish Orphan Biovitrum AB (publ) için analist derecelendirmeleri gerçekleştirdi, bunlar 5 güçlü al, 9 al, 4 tut, 1 sat ve 5 güçlü sat içermektedir
